Previous close | 297.90 |
Open | N/A |
Bid | 371.00 |
Ask | 379.00 |
Strike | 430.00 |
Expiry date | 2025-01-17 |
Day's range | 297.90 - 297.90 |
Contract range | N/A |
Volume | |
Open interest | 1 |
Let's look at five large-cap pharma/biotech companies slated to release quarterly results this week.
An increase in profits from Dupixent and further uptake of Eylea HD are likely to have aided Regeneron (REGN) in partially offsetting the decline in Eylea sales.
Regeneron (REGN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.